Skip to main content

Table 4 Real-world bedaquiline treatment success rates reported by post-licensure studies

From: Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China

StudyYear of PublicationStudy TypeCountryNumber of PatientsStudy PopulationComparatorEfficacy (Success Rate)
BDQSOC
WHO [28]2017Systematic literature review conducted in 2016Multi country205MDR and XDRNot mentioned61.0%
France45Not mentioned75.5%
South Africa195Not mentioned63.4%
Borisov et al. [12]2017Large retrospective, observational study conducted in 25 centers in 15 countries on 5 continentsAfrica113MDR and XDRNot mentioned64.6%
Eastern Europe85Not mentioned63.5%
Other settings49Not mentioned55.1%
Skrahina et al. [11]2018Study on 192 MDR-TB patients treated with bedaquilineBelarus192MDRNot mentioned92.7%
Diacon et al. [10]2014Phase 2b trialBrazil, India, Latvia, Peru, the Philippines, and Russia132 (66 each)MDRStandard-of-care drugs62.0%44.0%
58.0%32.0%
Guglielmetti et al. [14]2017Retrospective study of multicenter observational cohortFrance45MDR and XDRNot mentioned80%
Ndjeka et al. [15]2018Retrospective studySouth Africa200MDR and XDROnly bedaquiline69.5%
  1. Abbreviations: WHO World Health Organization; MDR-TB drug-resistant tuberculosis; XDR-TB extensively drug-resistant tuberculosis